The maintenance dose of Ozempic for weight loss is usually 1.0 mg per week. Some individuals may require an increase to 2.0 mg if recommended by their healthcare provider. Always adhere to the ...

SURPASS-2 was an open label, 40-week, phase-3 trial which randomized patients to receive once-weekly injections of Mounjaro at a dose of 5 mg, 10 mg, or 15 mg, or Ozempic at a dose of 1 mg.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation – which will be sold as Wegovy – is the first new medicine to be approved in the US ...

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Medically reviewed by Elizabeth Barnes, RDN Berberine is a natural compound in flowering plants like barberry, coptis root, ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...